Edinburgh Research Explorer

Tokyo Guidelines 2018 management bundles for acute cholangitis and cholecystitis

Citation for published version:

Digital Object Identifier (DOI):
10.1002/jhbp.519

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
Journal of Hepato-Biliary-Pancreatic Sciences

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Guideline

Tokyo Guidelines 2018 management bundles for acute cholangitis and cholecystitis


The author’s affiliations are listed in the Appendix.

Corresponding author:

Tadahiro Takada, MD, PhD, Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

E-mail: t-takada@jshbps.jp

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jhbp.519

This article is protected by copyright. All rights reserved.
Keywords: Cholangitis bundles, Cholecystitis bundles, Guidelines, Acute cholangitis, Acute cholecystitis

Abstract

Management bundles that define items or procedures strongly recommended in clinical practice have been used in many guidelines in recent years. Application of these bundles facilitates the adaptation of guidelines and helps improve the prognosis of target diseases. In Tokyo Guidelines 2013 (TG13), we proposed management bundles for acute cholangitis and cholecystitis. Here, in Tokyo Guidelines 2018 (TG18), we redefine the management bundles for acute cholangitis and cholecystitis. Critical parts of the bundles in TG18 include the diagnostic process, severity assessment, transfer of patients if necessary, and therapeutic approach at each time point. Observance of these items and procedures should improve the prognosis of acute cholangitis and cholecystitis. Studies are now needed to evaluate the dissemination of these TG18 bundles and their effectiveness.

Introduction

Detailed guidelines are now being released in many fields of medicine, and it is not easy for clinical physicians to keep all of the contents of these guidelines in mind when treating patients. Nevertheless, to improve patient prognosis, such guidelines need to be widely disseminated and used in clinical practice. Using bundles in health care simplifies complex patient care processes. A bundle is a selected set of elements of care that are distilled from evidence-based practice guidelines and that, when implemented as a group, have an effect on outcomes beyond that achieved when the individual elements are implemented alone.

We proposed management bundles for acute cholangitis and cholecystitis in Tokyo Guidelines 2013 (TG13) [1]. Here, as part of TG18, we propose a new flowchart for the treatment of acute cholecystitis and have made several changes to the clinical practice guidelines for managing acute cholangitis and acute cholecystitis.

This article is protected by copyright. All rights reserved.
Efficacy of the bundles

A good example for the effectiveness of using bundles is the sepsis bundles in the Surviving Sepsis Campaign Guidelines. Sepsis bundles were introduced in 2008, and improvements in compliance and survival with the bundles were investigated in a number of studies [2]-[6]. These reports showed a marked reduction in hospital mortality rates in patients whose care included compliance with most of the bundles.

To encourage adherence to clinical guidelines and improve care processes, the Institute for Healthcare Improvement developed the concept of “care bundles” [7] in critical care patients. Various strategies such as education (86%), reminders (71%), and audit and feedback (63%) have been used to encourage the implementation of the care bundles in intensive care units ([8], 26276569).

As with TG13, in the process of developing TG18, mandatory items or procedures to be included in the management bundles have been discussed and defined among Tokyo Guidelines Revision Committee members. On the basis of the recommendations in TG18, those items that are expected to yield favorable treatment results have been included in the bundles to assure the appropriate interventions for acute cholangitis and cholecystitis at the appropriate times. The TG13 checklists also have been updated to confirm compliance with the bundles.

Acute cholangitis management bundle (Table 1)

Few changes have been made in the TG18 management bundle for acute cholangitis compared with the TG13 one, with the exception of the addition of recommendations for patient transfer [9]. If acute cholangitis is suspected, perform a diagnostic assessment by using the TG18 diagnostic criteria [10]. If a definitive diagnosis cannot be made, reassess the patient every 6 to 12 h using the diagnostic criteria. Use the severity assessment criteria [9] to assess severity repeatedly: at diagnosis, within 24 h after diagnosis, and again during the next 24 to 48 h. Provide initial treatment, such as sufficient fluid replacement, electrolyte compensation, and intravenous administration of analgesics and full-dose antimicrobial agents, as soon as a diagnosis has been made [11]. Perform biliary drainage, and culture the blood or bile, or both, if the condition is sufficiently severe [12]. If the hospital is not equipped to
perform endoscopic or percutaneous transhepatic biliary drainage or to provide intensive care, transfer patients with moderate or severe cholangitis to a hospital that is capable of providing these treatments.

**Acute cholecystitis management bundle (Table 2)**

If acute cholecystitis is suspected, diagnostic assessment is made by using the TG18 diagnostic criteria [13]. If a definite diagnosis cannot be made, reassess the patient every 6 to 12 h using the diagnostic criteria. Use the severity assessment criteria [13] to assess the severity repeatedly: at diagnosis, within 24 h after diagnosis, and again at 24 to 48 h, and evaluate the surgical risk (e.g. presence of local inflammation, Charlson comorbidity index, American Society of Anesthesiologists physical status classification, or the predictive factors). Taking into consideration the need for cholecystectomy, as soon as a diagnosis has been made, initiate treatment, including sufficient fluid replacement, electrolyte compensation, fasting, and administration of intravenous analgesics and full-dose antimicrobial agents [11,13]. Urgent or early laparoscopic cholecystectomy (Lap-C), urgent or early biliary drainage, and blood or bile culture (or both) should be performed according to the severity and surgical risk [14-17]. Consider transferring the patient to advanced facilities if facilities for urgent or emergency Lap-C, biliary drainage, and intensive care are not available [14].

**Checklist for the use of management bundles for acute cholangitis and cholecystitis (Tables 3, 4)**

Checklists are given to ensure effective use of the bundles. Use of these lists in medical care ensures that standards are maintained and is thought to improve the effectiveness of the bundles. The TG13 checklists also have been updated to confirm compliance with the bundles [1]. A checklist of the procedures, laboratory tests, monitoring, and interventions required should be placed at the patient’s bedside.
Conclusions

Bundles consist of important items and procedures for the effective application of TG18. Reports from various facilities have demonstrated that improved prognosis can be expected through the use of the Tokyo Guidelines for acute cholangitis and cholecystitis.

Future evaluations of the distribution of TG18 bundles and of changes in prognosis will provide evidence for the future construction and revision of TG18.

Acknowledgments

We are grateful to the following organizations for their support and guidance in the preparation of TG18: the Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japanese Society for Abdominal Emergency Medicine, Japan Biliary Association, and Japan Society for Surgical Infection. We thank the Japanese Society of Hepato-Biliary-Pancreatic Surgery for managing this publication, and we thank the members of the secretariat of the Society for their technical support.

Conflicts of interest: None

Appendix

Toshihiko Mayumi, Department of Emergency Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan; Kohji Okamoto, Department of Surgery, Center for Gastroenterology and Liver Disease, Kitakyushu City Yahata Hospital, Fukuoka, Japan; Tadahiro Takada, Fumihiko Miura, and Keita Wada, Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan; Steven M. Strasberg, Section of Hepato-Pancreato-Biliary Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; Joseph S Solomkin, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA; David Schlossberg, Professor of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, Medical Director, TB Control Program, Philadelphia, PA, Department of Public Health, Philadelphia, PA, USA; Henry A. Pitt, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Masahiro Yoshida, Department of Hemodialysis and Surgery, Ichikawa Hospital, International University of Health and Welfare, Chiba, Department of EBM and Guidelines, Japan Council for Quality Health Care, Tokyo, Japan; Harumi Gomi, Center for Global Health, Mito Kyodo General Hospital, University of Tsukuba, Ibaraki, Japan; O James Garden, Clinical Surgery,

This article is protected by copyright. All rights reserved.
Accepted Article

University of Edinburgh, Edinburgh, UK; Seiki Kiriyama, Department of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan; Masamichi Yokoe, Department of General Internal Medicine, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan; Itaru Endo, Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Kanagawa, Japan; Horacio J. Asbun, Department of Surgery, Mayo Clinic College of Medicine, Florida, USA; Yukio Iwashita and Masafumi Inomata, Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan; Taizo Hibi, Department of Surgery, Keio University School of Medicine, Tokyo, Japan; Akiko Umezawa, Minimally Invasive Surgery Center, Yotsuya Medical Cube, Tokyo, Japan; Kenji Suzuki, Department of Surgery, Fujinomiya City General Hospital, Shizuoka, Japan; Takao Itoi and Shuntaro Mukai, Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan; Jiro Hata, Department of Endoscopy and Ultrasound, Kawasaki Medical School, Okayama, Japan; Ho-Seong Han and Yoo-Seok Yoon, Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea; Tsann-Long Hwang, and Miin-Fu Chen, Division of General Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Christos Dervenis, First Department of Surgery, Agia Olga Hospital, Athens, Greece; Koji Asai, Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan; Yasuhisa Mori, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Wayne Shih-Wei Huang, Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan; Giulio Belli, Department of General and HPB Surgery, Loreto Nuovo Hospital, Naples Italy; Palepu Jagannath, Department of Surgical Oncology, Lilavati Hospital and Research Centre, Mumbai, India; Daniel Cherqui, Hepatobiliary Center, Paul Brousse Hospital, Villejuif, France; Kazuto Koizaka, Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa Japan; Todd H. Baron, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, North Carolina, USA; Eduardo de Santibañes, Department of Surgery, Hospital Italiano, University of Buenos Aires, Buenos Aires, Argentina; Ryota Higuchi and Masakazu Yamamoto, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan; Dirk J. Gouma, Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands; Daniel J. Deziel, Department of Surgery, Rush University Medical Center, Chicago, IL, USA; Kui-Hin Liau, Liau KH Consulting PL, Mt Elizabeth Novena Hospital, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Go Wakabayashi, Department of Surgery, Ageo Central General Hospital, Saitama, Japan; Robert Padbury, Division of Surgical and Specialty Services, Flinders Medical Centre, Adelaide, South Australia, Australia; Eduard Jonas, Surgical Gastroenterology/Hepatopancreato/biliary Unit, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; Avinash Nivritti Supe, Department of Surgical Gastroenterology, Seth G S Medical College and K E M Hospital, Mumbai, India; Harjit Singh, Department of Hepato-Pancreato-Biliary Surgery, Hospital Selayang, Selangor, Malaysia; Toshifumi Gabata, Director, General Kanazawa University Hospital, Ishikawa, Japan; Angus C.W. Chan, Surgery Centre, Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong; Wan Yee Lau, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Sheung Tat Fan, Director, Liver Surgery Centre, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong; Chen-Guo Ker, Department of Surgery, Yuan’s General Hospital, Kaohsiung, Taiwan; In-Seok Choi, Department of Surgery, Konyang University Hospital, Daejeon, Korea; Myung-Hwan Kim, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul, Korea; Dong-Sup Yoon, Department of Surgery, Yonsei University Gangnam Severance Hospital, Seoul, Korea; Seigo Kitano, President, Oita University, Oita, Japan; Koichi Hirata, Department of Surgery, JR Sapporo Hospital, Hokkaido, Japan; Kazuo Inui, Department of

This article is protected by copyright. All rights reserved.
Gastroenterology, Second Teaching Hospital, Fujita Health University, Aichi, Japan; Yoshinobu Sumiyama, Director, Toho University, Tokyo, Japan.

References


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.

Table 1 Management bundle for acute cholangitis

1. When acute cholangitis is suspected, perform a diagnostic assessment every 6 to 12 h using TG18 diagnostic criteria until a diagnosis is reached.

2. Perform abdominal US, followed by a CT scan, MRI, MRCP, and HIDA scan as required.

3. Use the severity assessment criteria to assess severity repeatedly: at diagnosis, within 24 h after diagnosis, and from 24 to 48 h after diagnosis.

4. As soon as a diagnosis has been made, provide initial treatment. The treatment is as follows: sufficient fluid replacement, electrolyte compensation, and intravenous administration of analgesics and full-dose antimicrobial agents.

5. In patients with Grade I (mild) disease, if no response to the initial treatment is observed within 24 h, perform biliary tract drainage immediately.

6. In patients with Grade II (moderate) disease, perform biliary tract drainage immediately along with the initial treatment. If early drainage cannot be performed because of a lack of facilities or skilled personnel, consider transferring the patient.

7. In patients with Grade III (severe) disease, perform urgent biliary tract drainage along with the initial treatment and give general supportive care. If urgent drainage cannot be performed because of a lack of facilities or skilled personnel, consider transferring the patient.

8. In patients with Grade III (severe) disease, supply organ support (e.g. noninvasive/invasive positive pressure ventilation, use of vasopressors and antimicrobial agents) immediately.

9. Perform blood culture or bile culture, or both, in Grade II (moderate) and III (severe) patients.

10. Consider treating the etiology of acute cholangitis with endoscopic, percutaneous, or operative intervention once the acute illness has resolved. Cholecystectomy should be performed for cholecystolithiasis after the acute cholangitis has resolved.
11. If the hospital is not equipped to perform endoscopic or percutaneous transhepatic biliary drainage or provide intensive care, transfer patient with moderate or severe cholangitis to a hospital capable of providing these treatments.

**US, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; HIDA, hepatobiliary iminodiacetic acid**

**Table 2 Management bundle for acute cholecystitis**

1. When acute cholecystitis is suspected, perform a diagnostic assessment every 6 to 12 h using TG18 diagnostic criteria until a diagnosis is reached.

2. Perform abdominal US, followed by a CT scan or HIDA scan if needed to make a diagnosis.

3. Use the severity assessment criteria to assess severity repeatedly: at diagnosis, within 24 h after diagnosis, and from 24 to 48 h after diagnosis. Evaluate the surgical risk (e.g. local inflammation, CCI, ASA, PS, predictive factors).

4. Taking into consideration the need for cholecystectomy, as soon as a diagnosis has been made, initiate treatment, with sufficient fluid replacement, electrolyte compensation, fasting, and administration of intravenous analgesics and full-dose antimicrobial agents.

5. In Grade I (mild) patients, laparoscopic cholecystectomy (Lap-C) at an early stage, i.e. within 7 days (within 72 h is better) of onset of symptoms is recommended.

6. If conservative treatment is selected for patients with Grade I (mild) disease and no response to initial treatment is observed within 24 h, reconsider early Lap-C if patient performance status is good and fewer than 7 days have passed since symptom onset or biliary tract drainage.

7. In Grade II (moderate) patients, consider urgent/early Lap-C if patient performance status is good and the advanced Lap-C technique is available. If the patient’s condition is poor, urgent/early biliary drainage, or delayed/elective Lap-C, can be selected.
8. In Grade III (severe) patients with high surgical risk*, perform urgent/early biliary drainage. If there are neither negative predictive factors** nor FOSF*** and the patient has good PS, early Lap-C at an advanced center can be chosen.

9. Perform blood culture or bile culture, or both, in Grade II (moderate) and III (severe) patients.

10. Consider transferring the patient to advanced facilities if urgent/emergency Lap-C, biliary drainage, and intensive care are not available.

US, ultrasonography; CT, computed tomography; HIDA, hepatobiliary iminodiacetic acid; CCI, Charlson Comorbidity Index; ASA, American Society of Anesthesiologists class; PS, performance status

*high surgical risk: evaluate CCI, ASA, PS, predictive factors, and FOSF

**predictive factors: jaundice (T-Bil ≥ 2), neurological dysfunction, respiratory dysfunction

***FOSF: favorable organ system failure = cardiovascular or renal organ system failure that is rapidly reversible after admission and before early Lap-C in acute cholecystitis
Table 3 Acute cholangitis bundle checklist

- Repeat the diagnosis every 6 to 12 h

- Perform diagnostic imaging: abdominal US followed by CT scan, MRI, MRCP, and HIDA scan as needed.

- Assess severity at diagnosis, within 24 h; and from 24 to 48 h after diagnosis.

- After diagnosis, immediately start antibiotic administration and general supportive care.

- Grade I (mild): perform biliary drainage when no symptom improvement is observed within 24 h.

- Grade II (moderate): perform biliary drainage immediately.

- Grade III (severe): apply organ support and emergency biliary drainage.

- Consider transfer when the above procedures are unavailable.

- Grade II (moderate) and III (severe): culture blood or bile or both.

- Consider surgical procedures to remove causes after biliary drainage and amelioration of organ failure.
Table 4 Acute cholecystitis bundle checklist

- Repeat the diagnosis every 6 to 12 h.

- Perform diagnostic imaging: US, followed by CT and HIDA scan.

- Assess severity at diagnosis and within 24 h after diagnosis; repeat severity assessment every 24 h and evaluate surgical risk.

- Immediately initiate antibiotic administration and general supportive care.

- Grade I (mild): perform laparoscopic cholecystectomy (Lap-C) at an early stage within 7 days (within 72 h is better) of onset of symptoms.

- Conservative treatment for Grade I (mild): if condition is worsening or no improvement is observed within 24 h, reconsider early Lap-C if fewer than 7 days since biliary drainage (cholecystostomy).

- Grade II (moderate): perform urgent/early Lap-C if patient performance status is good and advanced Lap-C technique is available. If not, urgent/early biliary drainage or delayed/elective Lap-C can be selected.

- Grade III (severe): perform urgent/early biliary drainage in patients with high surgical risk. If there are neither negative predictive factors nor FOSF and the patient has a good PS, early Lap-C at an advanced center can be chosen.

- Grade II (moderate) and III (severe): culture blood or bile or both.

- Consider transferring the patient to advanced facilities if urgent/emergency Lap-C, biliary drainage, and intensive care are not available.